The Vanguard Group, Inc. recently announced the acquisition of new stake in Opko Health Inc (NASDAQ:OPK). The institutional investor has increased its shareholding in the Healthcare company by 0.04% to 38.58 million shares with purchase of 13628.0 shares. This fresh investment now brings its stake to 4.99% valued currently at $58.26 million. In addition, KSM Mutual Funds Ltd. raised its holdings by 0.33 million to 11.12 million shares. And SSgA Funds Management, Inc. has lifted its position by 2.12% or 0.19 million shares – to 9.34 million shares.
Currently, there are 772.65M common shares owned by the public and among those 410.05M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 105 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 105 of these insider trades were purchases, accounting for 3,720,245 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Opko Health Inc are Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Vanguard Small Cap Index Fund. Vanguard Total Stock Market ETF owns 12.73 million shares of the company’s stock, all valued at over $19.22 million. iShares Russell 2000 ETF sold 28998.0 shares to see its total holdings shrink to 10.95 million shares valued at over $16.54 million and representing 1.42% of the shares outstanding. Vanguard Small Cap Index Fund sold -0.12 million shares to bring its total holdings to over 9.84 million shares at a value of $14.86 million. Vanguard Small Cap Index Fund now owns shares totaling to 1.27% of the shares outstanding.
However, the script later moved the day high at 1.0200, up 1.30%. The company’s stock has a 5-day price change of 3.27% and -21.09% over the past three months. OPK shares are trading -33.11% year to date (YTD), with the 12-month market performance down to -31.29% lower. It has a 12-month low price of $0.85 and touched a high of $2.24 over the same period. OPK has an average intraday trading volume of 8.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.55%, -27.38%, and -35.87% respectively.
Institutional ownership of Opko Health Inc (NASDAQ: OPK) shares accounts for 24.56% of the company’s 772.65M shares outstanding. Mutual fund holders own 49.50%, while other institutional holders and individual stakeholders account for 6.56% and 18.06% respectively.
It has a market capitalization of $780.79M and a beta (3y monthly) value of 1.78. The earnings-per-share (ttm) stands at -$0.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.79% over the week and 8.80% over the month.
Analysts forecast that Opko Health Inc (OPK) will achieve an EPS of -$0.09 for the current quarter, -$0.06 for the next quarter and -$0.19 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.1 while analysts give the company a high EPS estimate of -$0.08. Comparatively, EPS for the current quarter was -$0.11 a year ago. Earnings per share for the fiscal year are expected to increase by 43.48%, and 14.62% over the next financial year. EPS should grow at an annualized rate of 12.00% over the next five years, compared to 3.51% over the past 5-year period.
Looking at the support for the OPK, a number of firms have released research notes about the stock. Barrington Research stated their Outperform rating for the stock in a research note on June 29, 2023, with the firm’s price target at $2.
